Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by RickyBobbyTOon Aug 12, 2022 9:31am
176 Views
Post# 34891001

RE:Quarterly on Schedule

RE:Quarterly on Schedule

this was way more honest than last years blindsided financing. Everyone knows they need cash, let the chips fall as they may. Good speed and good luck. We are almost mid august so bankers are returning to their desks, let it be quick and painless. 


pm1861 wrote: Hello all,

After reading the latest NR I am left feeling a bit disappointed.  While the release highlights the accomplishments ( and there are many), it did not provide any detail on the recent Arc deal.  Good that they will seek approval for additional sites for TIGRIS. Further, there seems to be some foreshadowing to another raise from the
company

"While the Company continues to maintain a low cost operating structure for its base business operations, it anticipates its operating costs to increase throughout 2022 as Spectral’s Tigris trial enrolment is expected to increase, combined with incremental costs associated with Dialco’s upcoming usability trial for DIMI and the increase in field resources for the marketing and commercialization activities of its RRT devices."

Hopefully it won't come to more dilution.  My conviction in this company is still strong. Just wanted a little bit more.

PM



 

<< Previous
Bullboard Posts
Next >>